(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA Artemis II tracker: Where is the Orion now and when will it reach the moon? - 2Iran war triggering Easter staycation boom
- 3Getting Your Youngsters' Future: Grasping Legacy Regulations
- 4These Are the Journalists Israel Has Killed Since the Start of the Iran War
- 5Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 5 Cell phones of the Year
- Famous Rough terrain Vehicles for 2024
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- Nigeria’s return to Windsor castle signals new era in UK economic partnership
- Pick Your Top Method for starting the Morning
- The Advancement and Effect of Dental Embed Innovation on Oral Wellbeing
- Internet goes (cocoa) nuts: The funniest reactions to 12 tonne theft of KitKat bars
- Ariana Grande to host 'Saturday Night Live' Christmas show with Cher as musical guest, returning after nearly 40 years
- Dental Embed Innovation: An Achievement in Helpful Dentistry
